Founded in 2019, Iambic Therapeutics (fka Entos) is disrupting the therapeutics landscape with its unique AI-driven drug-discovery platform. Iambic has assembled a world-class team that unites pioneering AI experts and experienced drug hunters with strong track records of success in delivering clinically validated therapeutics. The Iambic platform has been demonstrated to deliver high-quality, differentiated therapeutics to clinic with unprecedented speed and across multiple target classes and mechanisms of action. The Iambic team is advancing an internal pipeline of clinical assets to address urgent unmet patient needs.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 07/14/21 | $53,000,000 | Series A |
Catalio Capital Coatue Management Freeflow Ventures Nexus Venture Partners OrbiMed Advisors | undisclosed |
| 10/03/23 | $100,000,000 | Series B |
Abingworth Ascenta Capital Bill Rastetter Catalio Capital Management Coatue Management freeflow Gradiant Corporation Illumina Ventures Nexus Venture Partners NVIDIA OrbiMed Advisors | undisclosed |
| 06/24/24 | $50,000,000 | Series B Extension |
Abingworth Coatue Management Exor Ventures Illumina Ventures Mubadala Capital Nexus Venture Partners Qatar Investment Authority Tao Capital Partners | undisclosed |
